LIDE’s Functional Diagnosis platform helps drug R&D companies overcome two primary challenges.
- Evaluating the best indications for promising compounds
- Identifying companion diagnosis for recruitment strategies
Indication Screening with MiniPDX®:
While LIDE offers standard in-vitro and in-vivo screening studies, we also recommend adding our MiniPDX® Mouse Trial as part of the validation process before more costly investments in complex in-vivo studies.
|PDX||MiniPDX||3D cells or Organoids|
|Study Length||4-6 months||7 days||2-8 weeks|
|Primary Benefit||Gold standard validation for IND application||Predictive power of PDX but shorter turnaround time||Better representation of natural tumor environments vs 2D cell cultures|
Table: Comparison of PDX, Organoids and MiniPDX® technologies
*by calculation here.
LIDE is participating in a real-world-evidence project across hospitals all over China that will eventually reach 10,000+ patients. This opportunity provides LIDE access to fresh tumor samples, many with special genetic alterations or drug resistance that is critical for validating new drug candidates.
By leveraging MiniPDX® technology and LIDE’s growing tissue library, drug companies can quickly identify or further evaluate potential indications, for a fraction of the cost and time required of PDX studies.
Fig. LIDE Functional Diagnosis platform offering indication screening and bio-marker determination.
Read a Functional Diagnosis case study.